TG Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings reports show whether the company is making or losing money and growing revenue.
Earnings announcements let investors know how the business performed during the quarter.
Board elections and compensation votes show if shareholders approve how leaders run and are paid by the company.
Early clinical trial success for new drug forms can lead to future products and revenue if approved.
Successful late-stage drug trials can lead to FDA approval and new sales, making the company valuable.
Quarterly earnings reports show whether the company is making or losing money and growing revenue.
Earnings announcements let investors know how the business performed during the quarter.
Stocky reads TG Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
TG Therapeutics, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports Q2 2026 financial results for six months ended June 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.